BUDENOFALK Rectal foam (2017)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Budenofalk 2mg/dose rectal foam.
Qualitative and quantitative composition
Each dose of 1.2 g foam contains 2 mg of budesonide. Excipients with known effect: cetyl alcohol, propylene glycol. For the full list of excipients, see section 6.1.
Pharmaceutical form
Rectal foam, pressurised container. White to pale white, creamy firm foam.
Therapeutic indications
For the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.
Posology and method of administration
Posology Adults aged >18 years One actuation of 2 mg budesonide daily. Paediatric population Budenofalk 2mg rectal foam should not be used in children due to insufficient experience in this age group. ...
Contraindications
Budenofalk 2mg rectal foam must not be used in patients with: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hepatic cirrhosis.
Special warnings and precautions for use
Treatment with Budenofalk 2mg rectal foam results in lower systemic steroid levels than conventional oral glucocorticosteroid therapy with systemically acting corticoids. Transfer from other glucocorticosteroid ...
Interaction with other medicinal products and other forms of interaction
Pharmacodynamic interactions Cardiac glycosides The action of the glycoside can be potentiated by potassium deficiency. Saluretics Potassium excretion can be enhanced. Pharmacokinetic interactions Cytochrome ...
Fertility, pregnancy and lactation
Pregnancy Administration during pregnancy should be avoided unless there are compelling reasons for therapy with Budenofalk 2mg rectal foam. There are few data of pregnancy outcomes after oral administration ...
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
Undesirable effects
The following frequency conventions are used in the evaluation of undesirable effects: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare ...
Overdose
To date, no cases of overdose with budesonide are known.
Pharmacodynamic properties
Pharmacotherapeutic group: Intestinal antiinflammatory agents, corticosteroids acting locally ATC code: A07EA06 The exact mechanism of action of budesonide in the treatment of ulcerative colitis/procto-sigmoiditis ...
Pharmacokinetic properties
Absorption After oral application the systemic availability of budesonide is about 10%. After rectal administration the areas under the concentration time curves are about 1.5-fold higher than in historical ...
Preclinical safety data
Preclinical investigations on dogs have shown that Budenofalk 2mg rectal foam is well tolerated locally. Preclinical data in acute, subchronic and chronic toxicological studies with budesonide showed atrophies ...
List of excipients
Cetyl alcohol Citric acid monohydrate Disodium edetate Emulsifying wax Macrogol stearyl ether Propylene glycol Purified water Propellant: n-Butane Isobutane Propane
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years. After first opening: 4 weeks.
Special precautions for storage
Do not store above 25°C. Do not refrigerate or freeze. This is a pressurised container, containing inflammable propellant. Do not expose to temperature higher than 50°C, protected from direct sunlight. ...
Nature and contents of container
Aluminium pressurised container with metering valve together with 14 PVC applicators coated with white soft paraffin and liquid paraffin for administration of the foam and 14 plastic bags for hygienic ...
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Dr. Falk Pharma GmbH, Leinenweberstr. 5, 79108, Freiburg, Germany
Marketing authorization number(s)
PL08637/0011
Date of first authorization / renewal of the authorization
Date of first authorisation: 15 Jun 2006 Date of last renewal: 15 Jun 2011
Date of revision of the text
05/2017
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
